Xencor, Inc. — Q2 2014 Form 10-Q
Reporting period: Three and six months ended June 30, 2014; financial statements are unaudited. Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies using its XmAb platform. It had no approved products and no product-sale revenue.
Financial performance and liquidity
| Metric | Q2 2014 | Six months 2014 |
|---|---|---|
| Collaboration, license and milestone revenue | $0.824 million | $3.008 million |
| Research and development expense | $4.283 million | $8.511 million |
| General and administrative expense | $1.594 million | $3.317 million |
| Operating loss | $5.053 million | $8.820 million |
| Net loss | $5.044 million | $8.795 million |
| Operating cash flow | Not presented quarterly | $(10.767) million |
- At June 30, cash was $66.218 million; current assets were $66.680 million and current liabilities $5.946 million. Total liabilities were $10.851 million, primarily deferred revenue; capital lease obligations were $5,000 current, with no long-term balance.
- Cash decreased $11.757 million in the first half. Investing activities used $1.123 million; financing activities provided $0.133 million.
- Gross margin is not meaningful for this development-stage business; the filing reports no product sales or product gross profit.
Changes versus prior comparable periods
- Q2 revenue fell to $0.824 million from $3.921 million, principally because Q2 2013 included a $3.0 million MorphoSys milestone. First-half revenue declined to $3.008 million from $5.266 million, despite 2014 Merck milestone revenue of $0.5 million.
- Q2 R&D rose $0.149 million, with increased bispecific-program spending offset by lower XmAb5871 manufacturing costs. First-half R&D decreased $0.183 million: lower XmAb5871 and XmAb5574 costs were offset by higher XmAb7195 and bispecific spending.
- G&A increased to $1.594 million from $0.793 million in Q2 and to $3.317 million from $1.539 million in the first half, reflecting staffing, professional fees, and public-company costs.
- Prior-year comparisons are distorted by the 2013 exchange of convertible notes for preferred stock: the first half of 2013 included a $48.556 million loss on settlement and a $147.114 million deemed contribution to common stockholders. Thus, 2013 net loss was larger, while reported income attributable to common stockholders was affected by the noncash preferred-stock accounting. 2014 net loss per share was $(0.16) for Q2 and $(0.28) for the first half.
Outlook, risks and notable items
- Management expected existing cash, interest and certain potential milestone or contingent payments to fund operating expenses and capital needs through 2016. This estimate is based on assumptions that may prove inaccurate; the company said additional financing may be required and it could not fund complete development of its candidates from current cash alone.
- Expected milestones included preliminary XmAb5871 Phase 1b/2a rheumatoid arthritis results in the second half of 2014; preliminary XmAb7195 Phase 1a data by year-end 2014, with trial completion expected in 2015; and a planned XmAb7195 Phase 1b trial in 2015. These are forward-looking plans, not guarantees.
- Development spending may rise as clinical trials advance. Key risks include clinical efficacy, safety and enrollment uncertainty; regulatory approval; reliance on partners and third-party manufacturers; competition; intellectual-property claims; and the need for future capital. The filing cited XmAb5871 immunogenicity in 44% of Phase 1a subjects and reported gastrointestinal symptoms and an infusion-related reaction among safety observations.
- A June 2014 Catalent letter of intent covered approximately $1.6 million of XmAb7195 cGMP manufacturing, expected to begin in Q4 2014 with product delivery in the first half of 2015. Cancellation before manufacturing begins could trigger penalties of $100,000–$465,000. A San Diego office lease carries approximately $200,000 in total payments.
- The company reported no off-balance-sheet arrangements or legal proceedings. Management stated disclosure controls were effective at a reasonable-assurance level, while also describing remediation efforts for a previously identified material weakness in revenue-recognition controls.
Investor verification points
- Confirm collaboration revenue timing and milestones, including partner-level recognition and the Q2 statement amount of $0.824 million; MD&A presents rounded revenue of approximately $0.9 million.
- Track cash burn and test the assumptions behind the stated runway through 2016, including whether potential partner payments occur.
- Check clinical trial progress, safety and immunogenicity updates for XmAb5871 and XmAb7195, and advancement of bispecific candidates.
- Verify Catalent manufacturing timing, total costs and any cancellation exposure, as well as reliance on external manufacturers.
- Monitor remediation of the revenue-recognition material weakness and any subsequent control deficiencies or financial-statement revisions.